Feng Zhang

Feng Zhang is a pioneer in the development of CRISPR-Cas genome editing technologies for use in eukaryotic cells. His laboratory developed the first CRISPR-Cas9 system for mammalian genome editing, which has revolutionized biomedical research and opened new therapeutic possibilities. Zhang has continued to discover and characterize novel CRISPR systems including Cas12 and Cas13, expanding the genome engineering toolkit. His work has laid the foundation for CRISPR-based therapeutics now in clinical trials for various diseases including cancer.

张锋是将CRISPR-Cas基因组编辑技术应用于真核细胞的先驱。他的实验室开发了第一个用于哺乳动物基因组编辑的CRISPR-Cas9系统，彻底改变了生物医学研究并开辟了新的治疗可能性。张锋继续发现和表征包括Cas12和Cas13在内的新型CRISPR系统，扩展了基因组工程工具包。他的工作为目前正在进行包括癌症在内的各种疾病临床试验的CRISPR治疗奠定了基础。